UM  > 中華醫藥研究院
iRGD decorated lipid-polymer hybrid nanoparticles for targeted co-delivery of doxorubicin and sorafenib to enhance anti-hepatocellular carcinoma efficacy
Zhang J.1; Hu J.1,2; Chan H.F.3; Skibba M.2; Liang G.2; Chen M.1
2016
Source PublicationNanomedicine: Nanotechnology, Biology, and Medicine
ISSN15499634
Volume12Issue:5Pages:1303
Abstract

The combination of doxorubicin (DOX) with sorafenib (SOR) has proven an effective strategy to enhance anti-hepatocellular carcinoma (HCC) efficacy. However, respective in vivo pharmacokinetic profiles and different endocytosis capacities of these two drugs greatly hinder their current application. Herein, the tumor-targeting peptide iRGD decorated lipid-polymer hybrid nanoparticles (NPs) with a shell-core structure were developed for co-delivery of DOX and SOR (DOX+SOR/iRGD NPs). After the drug ratio was optimized, the stabilized DOX + SOR/iRGD NPs were prepared. Through the iRGD-integrin recognition, DOX + SOR/iRGD NPs showed synergistic cytotoxicity, pro-apoptotic ability and enhanced internalization rate in human liver cancer HepG2 cells. In vivo pharmacokinetic result demonstrated that an extended circulation and bioavailability of DOX + SOR/iRGD NPs than free drugs. More importantly, DOX + SOR/iRGD NPs significantly enhanced antitumor efficiency in HCC xenograft mouse models. Overall, this study describes a promising nanoparticulate drug co-delivery strategy to combine clinical anticancer drugs and enhance anti-HCC efficacy. © 2016 Elsevier Inc.

KeywordActive Targeting Doxorubicin Hepatocellular Carcinoma Irgd Peptide Sorafenib
DOI10.1016/j.nano.2016.01.017
URLView the original
Indexed BySCI
Language英语
WOS Research AreaScience & Technology - Other Topics ; Research & Experimental Medicine
WOS SubjectNanoscience & Nanotechnology ; Medicine, Research & Experimental
WOS IDWOS:000377409100014
The Source to ArticleScopus
Fulltext Access
Citation statistics
Cited Times [WOS]:38   [WOS Record]     [Related Records in WOS]
Document TypeJournal article
CollectionInstitute of Chinese Medical Sciences
Affiliation1.State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Taipa, Macau, China
2.Chemical Biology Research Center, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang, China
3.Department of Biomedical Engineering, Columbia University, NY, USA
First Author AffilicationInstitute of Chinese Medical Sciences
Recommended Citation
GB/T 7714
Zhang J.,Hu J.,Chan H.F.,et al. iRGD decorated lipid-polymer hybrid nanoparticles for targeted co-delivery of doxorubicin and sorafenib to enhance anti-hepatocellular carcinoma efficacy[J]. Nanomedicine: Nanotechnology, Biology, and Medicine,2016,12(5):1303.
APA Zhang J.,Hu J.,Chan H.F.,Skibba M.,Liang G.,&Chen M..(2016).iRGD decorated lipid-polymer hybrid nanoparticles for targeted co-delivery of doxorubicin and sorafenib to enhance anti-hepatocellular carcinoma efficacy.Nanomedicine: Nanotechnology, Biology, and Medicine,12(5),1303.
MLA Zhang J.,et al."iRGD decorated lipid-polymer hybrid nanoparticles for targeted co-delivery of doxorubicin and sorafenib to enhance anti-hepatocellular carcinoma efficacy".Nanomedicine: Nanotechnology, Biology, and Medicine 12.5(2016):1303.
Related Services
Recommend this item
Bookmark
Usage statistics
Export to Endnote
Google Scholar
Similar articles in Google Scholar
[Zhang J.]'s Articles
[Hu J.]'s Articles
[Chan H.F.]'s Articles
Baidu academic
Similar articles in Baidu academic
[Zhang J.]'s Articles
[Hu J.]'s Articles
[Chan H.F.]'s Articles
Bing Scholar
Similar articles in Bing Scholar
[Zhang J.]'s Articles
[Hu J.]'s Articles
[Chan H.F.]'s Articles
Terms of Use
No data!
Social Bookmark/Share
All comments (0)
No comment.
 

Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.